233 related articles for article (PubMed ID: 18407954)
1. Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment.
Xu Y; Sun Y; Yao L; Shi L; Wu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; He L; Li P; Xie Y
Ann Oncol; 2008 Aug; 19(8):1423-1429. PubMed ID: 18407954
[TBL] [Abstract][Full Text] [Related]
2. Association of CYP2D6*10 (c. 100 C>T) Genotype with Z-END Concentration in Patients with Breast Cancer Receiving Tamoxifen Therapy in Indonesian Population.
Yenny ; Panigoro SS; Purwanto DJ; Hidayat A; Louisa M; Andalusia R; Setiabudy R
Endocr Metab Immune Disord Drug Targets; 2019; 19(8):1198-1206. PubMed ID: 30843495
[TBL] [Abstract][Full Text] [Related]
3. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
Regan MM; Leyland-Jones B; Bouzyk M; Pagani O; Tang W; Kammler R; Dell'orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Neven P; Debled M; Maibach R; Price KN; Gelber RD; Coates AS; Goldhirsch A; Rae JM; Viale G;
J Natl Cancer Inst; 2012 Mar; 104(6):441-51. PubMed ID: 22395644
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Punglia RS; Burstein HJ; Winer EP; Weeks JC
J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
[TBL] [Abstract][Full Text] [Related]
5. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
Schroth W; Goetz MP; Hamann U; Fasching PA; Schmidt M; Winter S; Fritz P; Simon W; Suman VJ; Ames MM; Safgren SL; Kuffel MJ; Ulmer HU; Boländer J; Strick R; Beckmann MW; Koelbl H; Weinshilboum RM; Ingle JN; Eichelbaum M; Schwab M; Brauch H
JAMA; 2009 Oct; 302(13):1429-36. PubMed ID: 19809024
[TBL] [Abstract][Full Text] [Related]
6. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN
Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111
[TBL] [Abstract][Full Text] [Related]
7. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
Jin Y; Desta Z; Stearns V; Ward B; Ho H; Lee KH; Skaar T; Storniolo AM; Li L; Araba A; Blanchard R; Nguyen A; Ullmer L; Hayden J; Lemler S; Weinshilboum RM; Rae JM; Hayes DF; Flockhart DA
J Natl Cancer Inst; 2005 Jan; 97(1):30-9. PubMed ID: 15632378
[TBL] [Abstract][Full Text] [Related]
8. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy.
Kiyotani K; Mushiroda T; Sasa M; Bando Y; Sumitomo I; Hosono N; Kubo M; Nakamura Y; Zembutsu H
Cancer Sci; 2008 May; 99(5):995-9. PubMed ID: 18294285
[TBL] [Abstract][Full Text] [Related]
9. Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.
Helland T; Henne N; Bifulco E; Naume B; Borgen E; Kristensen VN; Kvaløy JT; Lash TL; Alnæs GIG; van Schaik RH; Janssen EAM; Hustad S; Lien EA; Mellgren G; Søiland H
Breast Cancer Res; 2017 Nov; 19(1):125. PubMed ID: 29183390
[TBL] [Abstract][Full Text] [Related]
10. No association between CYP2D6*10 genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment.
Toyama T; Yamashita H; Sugiura H; Kondo N; Iwase H; Fujii Y
Jpn J Clin Oncol; 2009 Oct; 39(10):651-6. PubMed ID: 19596663
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen.
Okishiro M; Taguchi T; Jin Kim S; Shimazu K; Tamaki Y; Noguchi S
Cancer; 2009 Mar; 115(5):952-61. PubMed ID: 19156902
[TBL] [Abstract][Full Text] [Related]
12. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism.
Gjerde J; Hauglid M; Breilid H; Lundgren S; Varhaug JE; Kisanga ER; Mellgren G; Steen VM; Lien EA
Ann Oncol; 2008 Jan; 19(1):56-61. PubMed ID: 17947222
[TBL] [Abstract][Full Text] [Related]
13. Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China.
Lan B; Ma F; Chen S; Wang W; Li Q; Fan Y; Luo Y; Cai R; Wang J; Yuan P; Zhang P; Li Q; Xu B
Int J Cancer; 2018 Nov; 143(10):2499-2504. PubMed ID: 29978573
[TBL] [Abstract][Full Text] [Related]
14. Toremifene, an Alternative Adjuvant Endocrine Therapy, Is Better Than Tamoxifen in Breast Cancer Patients with CYP2D6*10 Mutant Genotypes.
Li X; Li Z; Li L; Liu T; Qian C; Ren Y; Li Z; Chen K; Ji D; Zhang M; Wang J
Cancer Res Treat; 2024 Jan; 56(1):134-142. PubMed ID: 37591782
[TBL] [Abstract][Full Text] [Related]
15. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users.
Bijl MJ; van Schaik RH; Lammers LA; Hofman A; Vulto AG; van Gelder T; Stricker BH; Visser LE
Breast Cancer Res Treat; 2009 Nov; 118(1):125-30. PubMed ID: 19189212
[TBL] [Abstract][Full Text] [Related]
16. Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.
Park IH; Ro J; Park S; Lim HS; Lee KS; Kang HS; Jung SY; Lee S
Breast Cancer Res Treat; 2012 Jan; 131(2):455-61. PubMed ID: 21437611
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.
Ahern TP; Hertz DL; Damkier P; Ejlertsen B; Hamilton-Dutoit SJ; Rae JM; Regan MM; Thompson AM; Lash TL; Cronin-Fenton DP
Am J Epidemiol; 2017 Jan; 185(2):75-85. PubMed ID: 27988492
[TBL] [Abstract][Full Text] [Related]
18. Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients.
Kiyotani K; Mushiroda T; Imamura CK; Tanigawara Y; Hosono N; Kubo M; Sasa M; Nakamura Y; Zembutsu H
Breast Cancer Res Treat; 2012 Jan; 131(1):137-45. PubMed ID: 21947681
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
Gaston C; Kolesar J
Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
[TBL] [Abstract][Full Text] [Related]
20. Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment.
Stingl JC; Parmar S; Huber-Wechselberger A; Kainz A; Renner W; Seeringer A; Brockmöller J; Langsenlehner U; Krippl P; Haschke-Becher E
Curr Med Res Opin; 2010 Nov; 26(11):2535-42. PubMed ID: 20849243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]